OCALIVA Film-coated tablet Ref.[7573] Active ingredients: Obeticholic acid

Source: European Medicines Agency (EU)  Revision Year: 2023  Publisher: ADVANZ PHARMA Limited, Suite 17, Northwood House, Northwood Avenue, Santry, Dublin 9, Ireland

Product name and form

Ocaliva 5 mg film-coated tablets.

Ocaliva 10 mg film-coated tablets.

Pharmaceutical Form

Film-coated tablet.

Ocaliva 5 mg film-coated tablets: Yellow, 8 mm round tablet debossed with ‘INT’ on one side and ‘5’ on the other side.

Ocaliva 10 mg film-coated tablets: Yellow, 8 mm × 7 mm triangular tablet debossed with ‘INT’ on one side and ‘10’ on the other side.

Qualitative and quantitative composition

Ocaliva 5 mg film-coated tablets: Each film-coated tablet contains 5 mg of obeticholic acid.

Ocaliva 10 mg film-coated tablets: Each film-coated tablet contains 10 mg of obeticholic acid.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Obeticholic acid

Obeticholic acid is a selective and potent agonist for the farnesoid X receptor (FXR), a nuclear receptor expressed at high levels in the liver and intestine. FXR activation decreases the intracellular hepatocyte concentrations of bile acids by suppressing de novo synthesis from cholesterol, as well as, by increasing transport of bile acids out of the hepatocytes.

List of Excipients

Tablet core:

Microcrystalline cellulose (E460)
Sodium starch glycolate (Type A)
Magnesium stearate

Tablet coating:

Poly(vinyl alcohol), partially hydrolysed (E1203)
Titanium dioxide (E171)
Macrogol (3350) (E1521)
Talc (E553b)
Iron oxide yellow (E172)

Pack sizes and marketing

High-density polyethylene (HDPE) bottles with a child resistant polypropylene closure and an aluminium foil induction seal.

Pack size: 30 or 100 film-coated tablets.

Not all pack sizes may be marketed.

Marketing authorization holder

ADVANZ PHARMA Limited, Suite 17, Northwood House, Northwood Avenue, Santry, Dublin 9, Ireland

Marketing authorization dates and numbers

EU/1/16/1139/001
EU/1/16/1139/002
EU/1/16/1139/003
EU/1/16/1139/004

Date of first authorisation: 12 December 2016
Date of latest renewal: 09 November 2022

Drugs

Drug Countries
OCALIVA Austria, Canada, Estonia, Spain, Finland, France, Croatia, Ireland, Israel, Italy, Lithuania, Poland, Romania, United Kingdom, United States

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.